CPPA

CPPA is a dual-prodrug nanoassembly system designed for hypoxia-triggered immunogenic chemotherapy and immune modulation in cancer treatment. It is composed of a hypoxia-triggerable camptothecin (CPT)-based dimeric prodrug (CP) and a lipid-conjugated STAT3 antisense oligonucleotide (ASO) prodrug (PA). The system self-assembles into stable nanomicelles that are capable of delivering both agents directly to the tumor site. The hypoxia-triggered release of CPT induces immunogenic cell death, while the STAT3 inhibition by the ASO enhances the immune response. This combination therapy aims to improve tumor cell killing, promote immune cell infiltration, modulate the immunosuppressive tumor microenvironment, reverse drug resistance, and prevent metastasis.